On being a neurologist in Italy at the time of the COVID-19 outbreak by A. Bersano & L. Pantoni
SPECIAL EDITORIAL
On being a neurologist in Italy at the time of the
COVID-19 outbreak
Anna Bersano, MD, PhD, and Leonardo Pantoni, MD, PhD
Neurology® 2020;94:905-906. doi:10.1212/WNL.0000000000009508
Correspondence
Dr. Bersano
anna.bersano@gmail.com
Italy is facing its fifth week of crisis due to the Coronavirus disease (COVID-19) outbreak, with
affected patients and deaths near to 70,000 and 6,000, respectively,1 numbers that are increasing
every day. Whether government imposition of quarantines, travel bans, and lockdown
throughout the country will have effect in the next weeks in limiting the spreading of this disease
has still to be seen. Meanwhile, a great spirit of sacrifice is required to health care personnel, and
authorities have to manage resource allocation to rapidly increase the number of intensive care
beds to assist patients with COVID-19.2 Although operating rooms and a number of wards have
been turned into dedicated intensive units, beds and resources are hardly sufficient to satisfy the
needs of so many simultaneously critically ill patients.3,4 Notably, among infected people, about
10% are health workers, and their number is increasing, also due to the scarcity of efficacious
protective measures.
In this scenario, Italian neurologists are facing 2 different challenges. First, given the increasing
number of COVID-19 cases, they have to deal with patients with neurologic complications
from the disease. Neurologic disturbances such as loss of consciousness, headache, seizures,
ageusia, hyposmia, dysphagia, and muscle pain are being increasingly reported in patients with
COVID-19.5 Part of these signs and symptoms may be attributed to cerebral hypoxia due to
pulmonary failure. However, it has been hypothesized that COVID-19 can invade the CNS,
based on what is known about the severe acute respiratory syndrome (SARS) and Middle East
respiratory syndrome viruses and the fact that angiotensin-converting enzyme 2 receptors, the
functional receptor for SARS-CoV-2, are found in the central and peripheral nervous system
and skeletal muscle.6–8 Like other respiratory viruses, COVID-19 may enter the CNS through
hematogenous or retrograde neuronal routes, although there is increasing evidence that
COVID-19 may also invade peripheral nerve terminals.6,7 Therefore, neurologists should
suspect a COVID-19 infection in patients with neurologic disturbances and treat the disease’s
neurologic complications.
A second relevant challenge for Italian neurologists is due to the indirect consequences of the
focus that the Italian health care system and media have put on the COVID-19 emergency. A
great reorganization of the entire public health system is underway in many parts of Italy (of
note, the health system is regionalized in Italy, and each region has great autonomy to make
health care–related decisions).4 In many Italian regions, hospitals have been divided into
COVID+ and COVID-free ones; several stroke units and neurointensive care units have been
reorganized or even closed; and many neurologists have been reallocated to assist patients with
COVID-19. These measures have had a major impact on the organization of the usual emer-
gency networks for myocardial infarction, stroke, and major trauma. The new organization
centralizes stroke care so that patients with stroke will receive acute treatment and hospitali-
zation in a limited number of stroke units and hospitals.9 This system is different from the
current hub and spoke organization, and it cannot be seen as a typical mother-and-ship model
because patients will no longer be transferred back to the spokes because these are currently
shut down or they have been turned into COVID-19 wards. When this model was proposed
and implemented a few weeks ago in the Lombardia region, neurologists feared that these few
hub centers would rapidly fill up with patients, leading to a collapse of the system because of the
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limited availability of beds and personnel. Surprisingly, this
has not happened so far, as the number of patients needing
acute treatment for vascular, cardiac, and neurologic events
seems to have decreased considerably in the last few weeks.
The phenomenon has been seen throughout Italy, and it is
even more surprising considering that many patients with
COVID-19 have high D-dimer levels and may be at a higher
risk of cerebrovascular diseases.5 Italian neurologists are
wondering what are the reasons for this and hypothesize that
patients with TIA or mild strokes remain home because of
fear about going to the hospital during the outbreak and that
patients with very severe strokes and those who had preex-
isting disability are also left at home. Another possible ex-
planation is that patients with acute neurologic events and
severe respiratory distress are not recognized to have
a concurrent stroke. Of course, all these hypotheses will have
to be studied, but if these situations are true, we may expect
more patients with postacute complications and long-term
disability due to the lack of appropriate acute management
and implementation of secondary stroke prevention
interventions.
In addition, Italian neurologists, and especially their patients,
are affected by the suspension or decrease of nonurgent
medical visits and surgical interventions. This situation affects
patients with chronic neurologic diseases such as epilepsy,
multiple sclerosis, and movement disorders. In addition, ac-
cess to rehabilitation treatments is limited, both in the in-
patient (because rehabilitation beds are now used for patients
with respiratory problems) and outpatients settings (whose
activity was also heavily reduced). Who should assist these
patients, how to treat them, and whether this policy is ac-
ceptable for the health system are at present unclear.
All these issues mean that the COVID-19 pandemic will
negatively affect the care of patients with neurologic con-
ditions. How big will this impact be is not yet known, but
neurologists all over the world need to be prepared for it.
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